Nuclear-medicine progress report for quarter ending December 31, 1982

In this progress report, the synthesis and evaluation of a new class of radioiodinated phosphonium cations for myocardial perfusion imaging are described. Triphenyl(trans-1-(/sup 125/I)iodo-1-penten-5-yl)phosphonium iodide was prepared as a model agent by condensation of 1,5-(/sup 125/I)diiodo-1-pentene with triphenylphosphine. This new agent was evaluated in rats and showed rapid and pronounced myocardial uptake with a mean heart uptake of 5.50% injected dose/gm 5 min after injection. Iodothienyl-substituted long-chain fatty acids have also been evaluated as a new class of potential myocardial imaging agents in which radioiodine is stabilized by attachment to the 5-position of a terminal thiophene ring. Iodine-125 labeled 17-(iodothienyl)heptadecanoic acid (C/sub 17/) and 13-(iodothienyl)tridecanoic acid (C/sub 13/) were prepared and studied in rats. Three shipments of /sup 191/Os-osmate were made to Medical Cooperative investigators for fabrication of the /sup 191/Os-/sup 191m/Ir radionuclide generator. Twelve production runs of /sup 11/C were performed with the 86-inch cyclotron and 44 samples of /sup 11/C-labeled amino acids were prepared. In addition, five shipments of /sup 195m/Pt-cis-dichlorodiammineplatinum(II) were made to collaborators for evaluation of the pharmacologic properties of this antitumor agent and to monitor the effective therapeutic dose levels during tumor therapy. Seven /sup 125/I-and /sup 123m/Te-labeled fatty acids were prepared for evaluation in more » conjunction with collaborators at the Massachusetts General Hospital. « less